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Herpes simplex virus type 1 (HSV-1) is resistant to the antiviral effects of interferon (IFN)-, -, or -. The fact that ICP0
mutants replicate like wild-type virus in IFN-/ receptor knockout mice (Leib et al., 1999, J. Exp. Med. 189, 663) suggested
that ICP0 may serve a direct role in the resistance of HSV-1 to IFN. To test this hypothesis, the effects of IFN-, -, and -
were compared against wild-type HSV-1 and an ICP0 mutant virus, 7134. In Vero cells, 7134 was more sensitive to inhibition
by low doses of type I IFN (-/) or type II IFN (-) than vesicular stomatitis virus, a well-studied IFN-sensitive virus. At a
concentration of 100 U/ml, IFN-, -, or - reduced the efficiency of 7134 plaque formation by 120-, 560-, and 45-fold,
respectively. In contrast, none of the IFNs reduced wild-type HSV-1 plaque formation by more than 3-fold. Even when Vero
cells were infected with 10 pfu per cell, IFN- and - inhibited 7134 replication by over 100-fold, but inhibition by IFN-
decreased to less than 10-fold. While IFN- efficiently inhibited 7134 replication in primary mouse kidney and SK-N-SH cells,
IFN- did not inhibit 7134 to a comparable extent in these cells. ICP0 provided in trans from an adenovirus vector allowed
7134 to replicate efficiently in Vero cells in the presence of IFN-, -, or -. While IFN- or - efficiently repressed the ICP0
promoter-lacZ reporter gene in 7134 (i.e., 60-fold reduction in -galactosidase activity), ICP0 provided in trans almost
completely reversed IFN-mediated repression of the lacZ gene in 7134. The results suggest that the rate of ICP0 expressionhether
mentINTRODUCTION
Interferon (IFN)-, -, and - are secreted proteins that
play important roles in host resistance to viral infections.
IFN- or - is produced by most cells in the body as an
innate response to viral infection (Samuel, 1998). The 22
known isotypes of IFN- share 20 to 30% amino acid
homology with IFN-, and all achieve their biological
effects by binding to a common IFN-/ receptor that is
expressed on all nucleated cells (Farrar and Schreiber,
1993; Vilcek and Sen, 1996). Therefore, IFN- and - are
classified together as type I IFN. In contrast, IFN- is an
unrelated protein that is produced almost exclusively by
activated NK cells and T lymphocytes, and IFN- binds to
the type II IFN receptor expressed on all nucleated cells
(Farrar and Schreiber, 1993). Aside from its direct antivi-
ral functions, IFN- is also important as an immunoregu-
latory cytokine that helps regulate T-cell-mediated im-
mune responses (Farrar and Schreiber, 1993). Binding of
type I IFN to the IFN-/ receptor modifies the transcrip-
tional and translational environment in cells such that an
“antiviral state” is induced (Vilcek and Sen, 1996). The
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dressed at Department of Microbiology and Immunology, Tulane Uni-295importance of IFNs in antiviral defense in vivo is under-
scored by the fact that nearly all animal viruses have
evolved mechanisms to antagonize effectors of the IFN-
induced antiviral state (Gale and Katze, 1998; Tan and
Katze, 2000). For example, herpes simplex virus type 1
(HSV-1) encodes for two viral gene products, ICP34.5 and
US11 RNA, which specifically prevent the cellular
dsRNA-dependent protein kinase (PKR) from inducing its
antiviral effects (Cassady et al., 1998; Poppers et al.,
2000).
Since the molecular and biochemical characterization
of ICP34.5, direct biological evidence has been obtained
to support the hypothesis that one of ICP34.5’s primary
functions in viral replication is to prevent protein trans-
lation shutoff by activated PKR (Cassady et al., 1998; Leib
et al., 2000). Specifically, Leib et al. (2000) demonstrated
that HSV-1 ICP34.5 mutants replicate like wild-type vi-
rus in PKR knockout mice. Likewise, we were intrigued
by the observations of Leib et al. (1999) using a similar
“reverse complementation” approach to demonstrate that
HSV-1 ICP0 mutants replicate like wild-type virus in
interferon (IFN)-/ receptor knockout mice. Unlike
ICP34.5, however, there was no compelling molecular or
biochemical evidence to suggest that the HSV-1 imme-
diate-early (IE) protein, ICP0, should play a role in viralin infected cells in vivo may be critical in determining w
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ICP0 is a zinc-binding phosphoprotein and was ini-
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tially characterized as a promiscuous transcriptional ac-
tivator based on its ability to stimulate transcription from
viral IE, early (E), and late (L) promoters in transient
transfection assays (Cai and Schaffer, 1992; Jordan and
Schaffer, 1997). In the absence of ICP0, only 1 of every
50 pfu of ICP0 viruses produce plaques in Vero cells
(Sacks and Schaffer, 1987). In recent years, Everett and
colleagues have demonstrated that ICP0 achieves its
biological effects through degradation of cellular pro-
teins (Everett et al., 1998). Like the oncoproteins PML,
mdm-2, and BRCA-1, ICP0 belongs to the RING finger
family of proteins that direct key cellular proteins to be
ubiquitinated and proteolytically degraded (Freemont,
2000; Joazeiro and Weissman, 2000). Thus, ICP0’s func-
tion as a transcriptional activator is dependent on ubiq-
uitin-specific protease 7 and the cellular 26S proteasome
complex (Everett et al., 1998).
Although the studies of Leib et al. (1999) demonstrated
that an ICP0 virus replicated far better in IFN-/ re-
ceptor knockout mice than in isogenic controls, the
mechanisms that accounted for this observation were
not defined. An independent communication by Moss-
man et al. (2000) demonstrated that 1000 U/ml of IFN-
inhibited the replication of HSV-1 ICP0 mutants in Vero
cells, but did not inhibit the replication of HSV-1 VP16,
ICP22, vhs, or UL13 mutants to nearly the same
degree. Although these observations were intriguing, the
studies of Leib et al. (1999) and Mossman et al. (2000) left
many questions unaddressed. HSV-1 ICP0 mutants
have a long history of cell-specific and low multiplicity of
infection (m.o.i.)-dependent phenotypes (Cai and Schaf-
fer, 1991; Halford and Schaffer, 2000; Jordan et al., 1998;
Sacks and Schaffer, 1987; Yao and Schaffer, 1995).
Against this background, it was impossible to determine
whether the IFN-sensitive phenotype of ICP0 mutants
represented an important step toward elucidating the
role of ICP0 in the HSV life cycle or whether IFN sensi-
tivity was yet another conditional phenotype of ICP0
mutants.
The current investigation was undertaken to deter-
mine whether, in fact, ICP0 is essential for the resistance
of HSV-1 to IFN-/ and IFN-. The results of the present
study provide conclusive evidence that ICP0 is neces-
sary to prevent IFN/-mediated repression of HSV-1.
The sensitivity of the ICP0 mutant, 7134, to inhibition by
IFN-/ could not be overcome by increasing the m.o.i.,
and inhibition was observed in multiple cell types. Col-
lectively, the results indicate that ICP0’s function in the
HSV life cycle may lie in its capacity to override IFN-/
-mediated repression of the HSV genome at appropri-
ate times. The capacity of IFN-/ to efficiently repress
HSV-1 in the absence of ICP0 raises important questions
about the antagonistic roles of ICP0 and host IFNs in the
balance between latency and reactivation in vivo.
RESULTS
Effect of IFN-, -, or - on the replication of KOS
and 7134 in Vero cells
The capacity of human IFN-, -, or - to inhibit the
replication of KOS (wild-type HSV-1) and 7134 (an ICP0
virus) was compared in a plaque reduction assay on
Vero cells. IFN-, -, or - reduced the number of KOS
plaques formed on Vero cell monolayers by 2.6-, 2.3-, and
1.4-fold, respectively, relative to monolayers treated with
vehicle (culture medium only) (Figs. 1A and 1C). In con-
trast, treatment of Vero cells with IFN-, -, or - reduced
the number of plaques formed by 7134 by 120-, 560-, and
45-fold, respectively (Figs. 1A and 1C).
Similar trends were observed when viral titers of KOS
and 7134 were determined 24 h postinoculation (p.i.) of
vehicle- and IFN-treated Vero cells. Following inoculation
with 0.1 pfu per cell, KOS replicated to titers of greater
than 1  106 pfu/ml in Vero cells treated with vehicle or
IFN-, -, or - (Fig. 1B). Because ICP0 mutants repli-
cate poorly in Vero cells following inoculation with 0.1
pfu/cell (Sacks and Schaffer, 1987), 7134 only replicated
to titers of 1.3  104 pfu/ml in vehicle-treated Vero cells.
However, treatment of Vero cells with IFN-, -, and -
further reduced 7134 titers recovered from Vero cells by
390-, 420-, and 130-fold, respectively, relative to vehicle-
treated cells (Figs. 1B and 1C). Therefore, at a low m.o.i.,
both type I (-/-) and type II (-) IFN efficiently inhibited
the replication of 7134.
Inhibition of 7134 by IFN- or - is not m.o.i.-
dependent
The replication defect of ICP0 viruses is far less
evident when the m.o.i. is increased to 1 or more pfu
per cell (Cai and Schaffer, 1991; Sacks and Schaffer,
1987). Therefore, it was not evident whether (1) ICP0
was truly essential for HSV-1 to overcome the antiviral
states induced by IFN-, -, or -, or (2) IFN sensitivity
was another multiplicity-dependent phenotype of
ICP0 viruses (Cai and Schaffer, 1991; Sacks and
Schaffer, 1987). To distinguish between these possi-
bilities, the effects of human IFN-, -, or - were
compared in Vero cells inoculated with 1 or 10 pfu of
7134 per cell. At an m.o.i. of 1, treatment with IFN-, -,
or - reduced the 7134 titer recovered from Vero cells
by 430-, 690-, and 150-fold, respectively, relative to
vehicle-treated cells (Figs. 2A and 2B). Acyclovir (ACV),
a potent inhibitor of HSV DNA synthesis (Elion et al.,
1977), inhibited 7134 replication by 7000-fold at this
m.o.i. When the m.o.i. was increased to 10 pfu per cell,
IFN- or - still reduced 7134 titers recovered from
Vero cells by 120- and 150-fold, respectively (Figs. 2A
and 2B). At the increased m.o.i. of 10, IFN- treat-
ment of Vero cells only reduced 7134 titers by 9-fold,
but ACV still reduced 7134 titers by 4000-fold
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(Fig. 2). Therefore, the capacity of IFN-/ to inhibit
replication of an ICP0 virus is not multiplicity-depen-
dent, but inhibition by IFN- decreases to less than
10-fold when the m.o.i. of 7134 is increased to 10 pfu
per cell.
IFN-mediated repression of 7134 is alleviated when
ICP0 is provided in trans
The following experiments were performed to deter-
mine whether ICP0 provided in trans would overcome
the capacity of IFN-, -, or - to inhibit 7134 replication
in Vero cells. In the first set of experiments, IFN- inhib-
ited the replication of 7134 in Vero cells and the degree
of inhibition was dose-dependent (Fig. 3A). In contrast,
IFN- failed to inhibit the replication of 7134 to the same
extent in the Vero-derived, ICP0-complementing L7 cell
line (Samaniego et al., 1997). Thus, 320 U/ml IFN- was
required to reduce 7134 titers by more than 10-fold in L7
cells (Fig. 3A). When the replication of 7134 was com-
pared in Vero and L7 cells treated with multiple
FIG. 2. IFN-mediated inhibition of an ICP0 virus is not m.o.i.-depen-
dent. (A) Titers of 7134 in Vero cells infected at m.o.i.s of 1 or 10 pfu/cell
and pretreated with vehicle, 100 U/ml IFN-, -, -, or 300 M acyclovir
(ACV), as determined 24 h p.i. (n  4 replicates per group). The dashed
line indicates the lower limit of detection of the microtiter plaque assay.
(B) Average fold-inhibition in 7134 replication observed in Vero cells
infected with 1 or 10 pfu/cell of 7134 and treated with IFN-, -, or - or
ACV. One-way ANOVA followed by Tukey’s post hoc t test confirmed
that the fold-inhibition of 7134 by IFN-, -, or - was highly significant
(P  0.001) at both m.o.i.s of 1 and 10 pfu/cell.
FIG. 1. Effect of IFN-, -, or - on the replication of wild-type and
ICP0 viruses in Vero cells. (A) Relative number of KOS and 7134
plaques formed on Vero cell monolayers treated with vehicle or 100
U/ml of IFN-, -, or - (n  2 replicates per group). (B) Titers of KOS
and 7134 achieved in Vero cells treated with vehicle or 100 U/ml of
IFN-, -, or -, infected at an m.o.i.  0.1, and harvested at 24 h p.i.
(n  4 replicates per group). The dashed line indicates the lower limit
of detection of the microtiter plaque assay. (C) Efficacy of IFN-, -, or
- as inhibitors of KOS and 7134 replication in Vero cells as measured
by the average fold-inhibition in plaque formation and production of
infectious virus (i.e., titers at 24 h p.i.). One-way ANOVA followed by
Tukey’s post hoc t test confirmed that the fold-inhibition of 7134 by
IFN-, -, or - was highly significant for each (P  0.001).
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doses of IFN- or -, similar results were obtained (data
not shown). In the second set of experiments, adenoviral
vectors were used to provide ICP0 in trans.Wild-type and
mutant copies of ICP0 were delivered to Vero cells with
the adenoviral vectors Ad.TRE-ICP0 (expresses wild-type
ICP0) and Ad.TRE-n212 (expresses the first 211 of 775
amino acids of ICP0), respectively. IFN- inhibited the
replication of 7134 to the same extent in Vero cells
treated with vehicle (data not shown) or Ad.TRE-n212
(Fig. 3B). In contrast, ICP0 provided in trans from Ad.TRE-
ICP0 almost completely reversed IFN--mediated inhibi-
tion of 7134 replication in Vero cells (Fig. 3B). Likewise,
ICP0 provided in trans also prevented IFN- or - from
inhibiting 7134 replication in Vero cells (data not shown).
Therefore, lack of ICP0 function does, in fact, account for
7134’s sensitivity to repression by IFN-, -, or -.
7134 is more sensitive to inhibition by IFN-, -, or -
than vesicular stomatitis virus
The ICP0 virus, 7134, was far more sensitive to inhi-
bition by IFN-, -, or - than wild-type HSV-1, an IFN-
resistant virus. To put this observation into the context of
IFN-sensitive viruses, the following experiment was con-
ducted to determine how sensitive 7134 was relative to
vesicular stomatitis virus (VSV). At concentrations of up
to 100 U/ml, neither IFN-, -, nor - reduced the titer of
KOS in Vero cells by more than 10-fold (Table 1). Even at
1000 U/ml, only IFN- reduced KOS titers by greater than
10-fold. However, in the absence of ICP0, as little as 10
U/ml of human IFN-, -, or - reduced 7134 titers in Vero
cells by over 10-fold (Table 1). In contrast, 10 U/ml of
each IFN had only a minimal effect on VSV replication in
Vero cells (Table 1). For type I IFN, 100 U/ml of IFN- or
- was the lowest dose that produced more than a
10-fold inhibition of VSV replication in Vero cells (Table 1).
For type II IFN, 1000 U/ml was the lowest dose of IFN-
that inhibited VSV replication by more than 10-fold (Table
1). Thus, in Vero cells, 7134 was considerably more
sensitive to inhibition by low doses of IFN-, -, or -
than VSV.
To determine whether ICP0 conferred IFN resistance
upon HSV-1 by globally negating the IFN-induced antivi-
ral state, the capacity of Ad.TRE-ICP0 to complement VSV
replication in IFN-treated Vero cells was tested. Coinfec-
tion with Ad.TRE-ICP0 and VSV did not prevent IFN-, -,
or - from inhibiting VSV replication in Vero cells (Table
1). Therefore, the mechanism by which ICP0 overrides
IFN-mediated repression of HSV-1 is virus-specific and
does not negate all of the effector mechanisms of the
IFN-induced antiviral state.
ICP0 overrides IFN-mediated repression of the ICP0
promoter-lacZ gene in 7134
The following experiment was performed to distin-
guish between two mechanisms that could account for
the capacity of IFN-/ or IFN- to inhibit the replication
of 7134 in Vero cells. Specifically, the result could either
be a consequence of (1) IFNs directly blocking viral IE
gene expression from ICP0 mutants (Mossman et al.,
2000) or (2) inefficient expression of L gene products
FIG. 3. ICP0 provided in trans prevents IFN- from inhibiting the
replication of an ICP0 virus. (A) ICP0 provided in trans from L7 cells.
Vero and L7 cells were treated with the indicated concentrations of
IFN- and inoculated with 7134 (m.o.i.  0.1), and virus was harvested
from the infected cells at 24 h p.i. Two-way ANOVA confirmed that
fold-inhibition of 7134 in IFN--treated L7 cells was significantly differ-
ent than observed in IFN--treated Vero cells (P  0.001). (B) ICP0
provided in trans from adenoviral vectors. Vero cells were treated with
the indicated concentrations of IFN- and inoculated with 7134 (m.o.i.
 0.1), and Vero cells were coinfected with Ad.TRE-n212 or Ad.TRE-
ICP0. Virus was harvested from the infected cells at 24 h p.i. For all
treatment groups, the viral titer was determined by plaque assay, and
the data are expressed as the mean  se of the fold-reduction in viral
titer observed in three replicate cultures per dose of IFN-, relative to
cultures that were not treated with IFN (n  6 per control). Two-way
ANOVA confirmed that coinfection with Ad.TRE-ICP0 versus Ad.TRE-
n212 produced significant differences in the fold-inhibition of 7134 in
IFN--treated Vero cells (P  106).
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from ICP0 mutants such that PKR is efficiently activated
and suppresses HSV-1 replication. Regarding the latter
hypothesis, expression of two viral L genes that encode
for. US11 RNA and ICP34.5 is necessary to prevent PKR
from inducing a host shutoff in protein translation in
neuronal cells (Poppers et al., 2000).
The capacity of IFN- or - to inhibit the ICP0 promot-
er-lacZ reporter gene in 7134 was compared (1) in the
presence or absence of Ad.TRE-ICP0 and (2) in the pres-
ence or absence of ACV which blocks L gene expression
via inhibition of viral DNA replication. At 24 h p.i., -gal
activity in vehicle-treated Vero cells infected with 7134
was 300-fold above background (Fig. 4). However, in
the absence of ICP0, treatment with IFN- or - reduced
-gal expression from 7134 to just 4.3- and 4.5-fold above
background, respectively (Fig. 4). Likewise, in ACV-
treated Vero cells, treatment with IFN- or - reduced
-gal expression to just 4.0- and 6.4-fold above back-
ground, respectively (Fig. 4). In contrast, when ICP0 was
provided from Ad.TRE-ICP0, treatment with IFN- or -
had little effect on -gal expression (i.e.,200-fold above
background; Fig. 4). Likewise, even in the presence of
ACV, Ad.TRE-ICP0 almost completely reversed the inhib-
itory effects of IFN- or - on -gal expression from the
ICP0 promoter-lacZ gene in 7134 (Fig. 4). Indeed, while
the presence or absence of ACV had little effect on -gal
expression, ICP0 was essential to prevent IFN- or -
from causing a 50- to 70-fold reduction in -gal expres-
sion from 7134. Thus, the capacity of ICP0 to antagonize
IFN-mediated repression of the ICP0 promoter-lacZ gene
TABLE 1
Relative Sensitivity of KOS, 7134, and VSV to Inhibition by IFN-, -, or -
(U/ml)b KOS, Vehicle
7134 VSV
Vehicle Ad.TRE-ICP0c Vehicle Ad.TRE-ICP0
IFN- 1 1.4 0.3a 3.8 1.2 0.9 0.3 1.0 0.1 NDd
10 0.9 0.3 11 8.7 1.2 0.1 1.8 0.3 ND
100 1.2 0.1 103 40 2.0 0.3 52 19 130 40
1000 6.0 1.1 440 190 2.3 0.6 610 220 ND
IFN- 1 1.1 0.3 4 2 1.0 0.0 0.9 0.1 ND
10 1.5 0.3 43 16 1.3 0.1 4.6 0.5 ND
100 5.9 0.6 230 60 2.0 0.1 1700 560 3200 1000
1000 28 7.9 550 250 2.5 0.3 12,000 3300 ND
IFN- 1 1.4 0.5 11.1 1 1.3 0.4 1.2 0.3 ND
10 2.1 0.4 34 6 1.1 0.4 3.0 0.7 ND
100 4.6 0.3 96 40 2.8 0.9 6.0 1.3 22 9
1000 2.6 0.1 240 60 2.8 0.3 58 21 ND
a Mean  se of the fold-reduction in viral titers observed in four replicates per group. Cultures were infected at a m.o.i. of 0.1 pfu/cell with KOS,
7134, or VSV and viral titers were determined 24 h p.i. Fold-reduction in each culture was calculated as the “average viral titer in vehicle-treated cells”
divided by the “viral titer in that culture.” Treatments that produced greater than 10-fold inhibition of virus replication are shown in boldface type.
b Vero cells were treated with 1, 10, 100, or 1000 U/ml of human IFN-, IFN-, or IFN-.
c At the time of infection, Vero cells were superinfected with Ad.TRE-ICP0 and Ad.CMV-rtTA (m.o.i.  10 each), and Vero cells were incubated in
medium containing 1 M doxycycline.
d Not determined.
FIG. 4. ICP0 overrides the capacity of IFN- or IFN- to repress -gal
expression from 7134. -Galactosidase expression from 7134 (m.o.i. 
1 pfu/cell) was compared in Vero cells treated with vehicle, 100 U/ml
IFN-, or 100 U/ml IFN- and secondarily treated with Ad.TRE-ICP0
(m.o.i.  10) and/or 300 M ACV. Vero cells were harvested 24 h p.i.
(n  6 replicates per group), and -galactosidase activity was mea-
sured in a colorimetric assay. One “relative unit of -gal activity” is
equal to the lower limit of detection of the assay, as determined in the
twofold dilution series used to generate the standard curve. At 1 h p.i.,
-galactosidase activities in 7134-infected Vero cells were not statisti-
cally different from uninfected Vero cells. One-way ANOVA followed by
Tukey’s post hoc t test confirmed that (1) treatment with IFN- or IFN-
significantly reduced -gal activity in 7134-infected cells (P  106)
and (2) treatment with Ad.TRE-ICP0 significantly increased -gal activ-
ity in 7134-infected cells treated with IFN- or IFN-.
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in 7134 is not dependent on the efficient expression of
viral L genes.
Effect of IFN- or - on the replication of KOS and
7134 in primary mouse kidney cells
A final set of experiments was performed to determine
whether the IFN-sensitivity of 7134 was unique to Vero
cells or whether it was a more general property of ICP0
viruses. The capacity of 7134 to form plaques on primary
mouse kidney (PMK) cells was compared to that of Vero
cells following treatment with vehicle, IFN-, or IFN-.
While an average 1 in 62 pfu of 7134 formed plaques on
vehicle-treated Vero cells, 1 in 2 pfu of 7134 formed
plaques on vehicle-treated PMK cells (Table 2). In con-
trast, only 1 in 340 pfu of 7134 formed plaques on PMK
cells treated with mouse IFN- (Table 2). Although hu-
man IFN- reduced the frequency with which 7134 forms
plaques on Vero cells to 1 in 11,000 pfu, the relative
magnitude of IFN-’s inhibitory effect in Vero cells was
180-fold and was thus comparable to the 170-fold inhibi-
tion observed in PMK cells (Table 2). In contrast, mouse
IFN- did not reduce the efficiency of 7134 plaque for-
mation on PMK cells to nearly the same extent that
human IFN- inhibited 7134 plaque formation on Vero
cells (Table 2).
The replication of KOS and 7134 in PMK cells treated
with vehicle, IFN-, or IFN- was compared relative to
Vero cells. As observed in Vero cells, KOS replicated to
titers of greater than 1  105 pfu/ml in PMK cells treated
with vehicle, IFN-, or IFN- (Table 3). Although 7134
replicated to comparable titers in vehicle-treated PMK
cells, the titer of 7134 in vehicle-treated Vero cells was
only 5 103 pfu/ml (Table 3). In both Vero and PMK cells,
IFN- reduced 7134 titers by 810- and 350-fold, respec-
tively (Table 3). Although treatment with human IFN-
inhibited the replication of 7134 in Vero cells by 130-fold,
mouse IFN- only reduced 7134 titers in PMK cells by
16-fold (Table 3). Likewise, similar comparisons on a
human neuron-derived cell line, SK-N-SH, revealed that
while human IFN- inhibited 7134 replication by 110-fold,
human IFN- only inhibited 7134 replication by 3-fold
(data not shown). Thus, while type I IFN efficiently inhib-
ited 7134 replication in three different cell types, IFN-
only achieved a comparable level of inhibition in Vero
cells.
DISCUSSION
ICP0 is essential for the resistance of HSV-1 to IFN
i. Type I IFN. Type I IFN (- or -) binds to the IFN-/
receptor and is produced by essentially all nucleated
cells in the body as an innate response to viral infection.
Although type I IFN has measurable effects on HSV-1
replication and gene expression (De Stasio and Taylor,
1990; Noisakran and Carr, 2000), it is a poor inhibitor of
TABLE 2
Effect of IFN- or - on 7134 Plaque Formation in Vero and
Primary Mouse Kidney (PMK) Cells
Treatmenta
Vero cells PMK cells
Plaques/
pfub
Fold-
inhibitionc
Plaques/
pfu
Fold-
inhibition
Vehicle 1 in 62 — 1 in 2 —
IFN- 1 in 11,000 180 1 in 340 170
IFN- 1 in 2,900 47 1 in 10 5
a Vero cells were treated with vehicle or 100 U/ml of human IFN-
or -. PMK cells were treated with vehicle or 100 U/ml of mouse IFN-
or -.
b The average frequency with which 7134 forms plaques on mono-
layers of Vero and PMK cells was determined as follows. Half-log
dilutions (i.e., 3.2-fold) of 7134 were added to Vero and PMK cell
monolayers treated with vehicle, IFN-, or IFN- (n  3 per group).
Plaque counts were determined in the first dilution of 7134 that yielded
a countable number. The quantity plaques/pfu was derived by dividing
the number of plaques observed in this well by the actual titer of the
viral inoculum, as determined on L7 cells. The coefficient of variation
for this measure ranged from 9 to 25% in the six treatment groups.
c Fold-inhibition was calculated by dividing [plaques/pfu in the vehi-
cle group] by [plaques/pfu in each IFN treatment group].
TABLE 3
Effect of IFN- or - on the Replication of KOS and 7134 in Vero and PMK Cells
Treatmenta
Vehicle IFN- IFN-
KOS (ICP0) Vero 5.66 0.12b 5.09 0.16 (3.8)c 5.18 0.11 (3.0)
PMK 5.82 0.10 5.16 0.13 (4.6) 5.53 0.27 (1.9)
7134 (ICP0) Vero 3.73 0.07 0.82 0.38 (810) 1.61 0.14 (130)
PMK 5.23 0.15 2.68 0.19 (350) 4.02 0.05 (16)
a Vero cells were treated with vehicle or 100 U/ml of human IFN- or -. PMK cells were treated with vehicle or 100 U/ml of mouse IFN- or -.
b Mean se of the logarithm of viral titers observed in four replicates per group. Cultures of Vero or PMK cells were infected at a m.o.i. of 0.1 pfu/cell
with KOS or 7134, and viral titers were determined 24 h p.i.
c Fold-inhibition is shown in parentheses and was calculated as 10([log titer in vehicle]  [log titer in IFN-treated]).
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viral replication relative to antiviral drugs such as ACV.
Although HSV’s resistance to IFN is often considered an
innate property of the virus, a growing body of evidence
demonstrates that this resistance is an active process.
Among the mechanisms by which IFNs inhibit viral rep-
lication (Samuel, 1991), PKR is a key cellular factor in the
activation of the antiviral state (Gale and Katze, 1998).
HSV-1 possesses two L gene products, ICP34.5 and
US11 RNA, which specifically counteract PKR and pre-
vent downstream effects such as phosphorylation of
eIF-2 and inhibition of protein translation (Cassady et
al., 1998; Poppers et al., 2000). Although ICP34.5 and
US11 RNA contribute to HSV’s resistance to the IFN-
induced antiviral state, these L gene products would not
be available to prevent IFNs from inhibiting earlier
phases of viral replication. The results of the present
study demonstrate that a viral IE protein, ICP0, is neces-
sary for HSV-1’s resistance to type I IFN. Thus, type I IFN
inhibited the replication of an ICP0 virus, 7134, by more
than 100-fold in Vero, PMK, and SK-N-SH cells.
Analysis of -gal expression from the ICP0 promoter-
lacZ gene in 7134 provided an important clue regarding
the mechanism of action of ICP0. Although IFN- effec-
tively blocked -gal expression in 7134-infected cells,
ICP0 provided in trans restored -gal expression to nor-
mal levels (Fig. 4). The mechanism by which ICP0 re-
stores -gal expression to 7134 is not blocked by ACV
and is thus not dependent on events that occur after viral
DNA synthesis (e.g., expression of ICP34.5 or US11
RNA). Although ICP0 could have stimulated multiple
steps in lacZ gene expression, there is no precedent for
ICP0 to stimulate gene expression by any mechanism
other than increased initiation of mRNA synthesis (Jor-
dan and Schaffer, 1997). Therefore, the results suggest
that IFN- transcriptionally represses the ICP0 promoter-
lacZ gene in 7134, but ICP0 provided in trans overrides
this repression and restores lacZ mRNA transcription to
normal levels. Consistent with this hypothesis, Mossman
et al. (2000) observed that while IFN- efficiently re-
pressed transcription of ICP4 and ICP27 mRNA from an
ICP0 mutant, it had little effect on IE mRNA transcription
from wild-type HSV-1. Therefore, efficient expression of
HSV-1 IE genes in the presence of type I IFN appears to
be highly dependent on the synthesis of the ICP0 protein.
It remains to be determined whether repression of IE
gene expression is the only mechanism by which type I
IFN inhibits HSV-1 replication.
ii. Type II IFN. IFN- is produced almost exclusively by
activated NK cells and T lymphocytes and binds to the
type II IFN receptor that is present on all nucleated cells
(Farrar and Schreiber, 1993). In the absence of ICP0,
IFN- inhibited the replication of 7134 in Vero cells by
more than 100-fold. However, inhibition by IFN- de-
creased to less than 10-fold when the m.o.i. of 7134 was
increased to 10 pfu/cell. Likewise, IFN- only modestly
inhibited the replication of 7134 in PMK and SK-N-SH
cells. Given the conditional nature with which IFN-
inhibited the replication of 7134, it is not evident that
resistance to IFN- is a relevant function of ICP0 in vivo.
The role of ICP0 in HSV-1 replication
ICP0 belongs to the RING finger family of proteins that
direct key cellular proteins to be ubiquitinated and pro-
teolytically degraded (Freemont, 2000; Joazeiro and
Weissman, 2000). Indeed, all known biological effects of
ICP0 are dependent on ICP0’s interaction with a ubiq-
uitin-specific protease and activation of the 26S protea-
some (Everett et al., 1998). Although ICP0 is normally
required for efficient HSV-1 replication in Vero cells, this
requirement can be bypassed by treatment of Vero cells
with 5 mM hexamethylene bis-acetamide (Smiley and
Duncan, 1997) or release from isoleucine deprivation
(Cai and Schaffer, 1991). Likewise, treatment with nerve
growth factor allows ICP0 mutants to replicate like
wild-type virus in PC12 cells (Jordan et al., 1998). Al-
though U2OS cells have been considered unique in their
ability to provide an “ICP0-complementing activity” that
allows ICP0 mutants to replicate like wild-type virus
(Yao and Schaffer, 1995), the results of this study dem-
onstrate that an ICP0 mutant also replicates like wild-
type virus in PMK cells (Table 3).
While many facts have accumulated about ICP0 in the
past 15 years, a fundamental question has remained
unanswered: “What biological function does ICP0 serve
in HSV replication?” Based on the results of this and
other in vitro studies (De Stasio and Taylor, 1990; Moss-
man et al., 2000; Preston and Nicholl, 1997), we propose
that ICP0 provides a mechanism for HSV to override
IFN-mediated repression at appropriate times. While the
behavior of ICP0 mutants in IFN-/ receptor knockout
mice (Leib et al., 1999) leaves little room to doubt that
ICP0 antagonizes the innate IFN response in vivo, the
precise role of this function in the HSV-1 life cycle re-
mains to be determined.
Role of ICP0 in the balance between latency and
reactivation of HSV-1
The HSV-1 genome is acutely sensitive to IFN-medi-
ated repression in the absence of ICP0. For example,
while 1 in 3 pfu of KOS formed plaques in the presence
of IFN-, 7134 was 170 times less likely to initiate a
productive infection in Vero and PMK cells treated with
IFN- (Table 2). This result suggests a logical mecha-
nism by which HSV-1 may establish latency in vivo. Like
other cells, neurons express IFN- as an innate re-
sponse to treatment with double-stranded RNA or virus
infection (Ward and Massa, 1995). If ICP0 is necessary to
antagonize the innate IFN response, then one would
predict that failure to rapidly express ICP0 would render
the HSV genome highly sensitive to repression by IFN-
/. Thus, in the same way that ICP0 is necessary and
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sufficient for HSV-1 reactivation from neuronal latency
(Halford et al., 2001; Halford and Schaffer, 2001), it may
prove that repression of ICP0 is necessary and sufficient
for HSV-1 genomes to enter the transcriptionally re-
pressed state of neuronal latency.
In light of this hypothesis, it is especially interesting
that two consensus interferon-stimulated response ele-
ments (ISREs) occur 300 bp downstream of the
latency-associated transcript (LAT) promoter. Thus, IFN-
/ may not only suppress viral IE promoters, but may
also stimulate the production of LAT RNAs. Because
absence of ICP0 protein allows IFN to repress HSV IE
promoters, this suggests a potential mechanism by
which LAT RHAs could facilitate the maintenance of
HSV-1 latency (Garber et al., 1997; Sawtell and Thomp-
son, 1992; Thompson and Sawtell, 1997). If the require-
ments for maintaining HSV-1 latency are simply (1) re-
pression of ICP0 expression and (2) repression of IE
promoters by IFN-associated factors, the LAT RNAs
could theoretically fulfill both functions through (1) anti-
sense repression of ICP0 mRNA translation (Farrell et al.,
1991; Mador et al., 1998) and (2) the formation of double-
stranded RNA structures (Daly and Reich, 1993; Gale and
Katze, 1998), respectively. Further investigation will be
required to determine if these hypotheses have any rel-
evance to the mechanisms by which HSV-1 establishes
and/or maintains latency in vivo.
MATERIALS AND METHODS
Cells, viruses, and interferons
Vero, 293, SK-N-SH, and L7 cells (Samaniego et al.,
1997) were propagated in complete DMEM containing
0.15% HCO3
 supplemented with 10% fetal bovine serum
(FBS), penicillin G (100 U/ml), streptomycin (100 mg/ml),
and 2 mM L-glutamine. Cultures of primary mouse kidney
cells were established by standard dissociation methods
and were also propagated in complete DMEM. Vesicular
stomatitis virus, wild-type HSV-1 strain KOS (Smith, 1964),
and the KOS-derived ICP0 mutant, 7134 (Cai and Schaf-
fer, 1989), were propagated in Vero cells. Titers of KOS
were determined on Vero cells, whereas titers of 7134
had to be determined on L7 cells, an ICP0-complement-
ing cell line, to accurately enumerate the number of
infectious particles that can enter cells. Thus, all refer-
ences to 7134 pfu (and m.o.i.) herein are based on these
L7-determined titers. It should be noted that while earlier
investigations which predated the construction of L7
cells (Samaniego et al., 1997) commonly defined the titer
of ICP0 mutants as enumerated on Vero cells, this
definition is now obsolete. With the development of sev-
eral methods to provide ICP0 in trans, standard virolog-
ical method dictates that titers of ICP0 mutant viruses
should be defined under conditions that allow the viral
mutants to most efficiently complete their replication
cycle.
Replication-defective adenoviral vectors were propa-
gated in 293 cells. The adenoviral vectors used in this
study, Ad.TRE-ICP0 and Ad.TRE-n212, were used to de-
liver wild-type and mutant forms of ICP0 (i.e., n212) to
Vero cells, respectively. The doxycycline-activated trans-
activator of the TRE promoter, rtTA, was expressed from
a second adenoviral vector Ad.CMV-rtTA (Halford et al.,
2001). Expression of ICP0 and n212 was achieved by
coinfection with either Ad.CMV-rtTA and Ad.TRE-ICP0 or
Ad.CMV-rtTA and Ad.TRE-n212 (m.o.i.  10 each) and
treatment with 1 M doxycycline.
Recombinant human universal IFN- (hybrid con-
structed from IFN-A and IFN-D), human IFN-, human
IFN-, mouse IFN-, and mouse IFN- (PBL Biomedical
Laboratories, New Brunswick, NJ) were used at concen-
trations of 100 U/ml, unless specifically indicated other-
wise. For all experiments, (1) IFNs were added to cul-
tures of Vero, primary mouse kidney, or SK-N-SH cells
14 h prior to HSV-1 infection, (2) cultures were inoculated
with virus in the absence of IFN, and (3) IFN treatment
was resumed immediately following inoculation.
Plaque reduction and virus replication assays
For plaque reduction assays, 2.5 105 Vero cells were
seeded in each well of a 6-well plate, and after 6 h, 100
U/ml of IFN-, IFN-, or IFN- was added to the culture
medium. After 14 h, Vero cell monolayers were infected
with 102 pfu KOS. Because IFNs inhibited 7134 to a
greater extent, multiple Vero cell monolayers were each
inoculated with different dilutions of 7134 (i.e., 5  103,
5  104, or 5  105 pfu). Because only 1 in 50 pfu of
7134 form plaques on Vero cells, the 5  103 pfu inocu-
lum produced only100 plaques on vehicle-treated Vero
cells. After inoculation, the cells were overlaid with cul-
ture medium containing 0.5% methylcellulose and 100
U/ml of the same IFN, and the number of plaques was
determined 3 to 4 days later.
For virus replication assays, 4  104 Vero cells were
seeded in each well of a 24-well plate, and after 6 h,
IFN-, IFN-, or IFN- was added to the culture medium.
After 14 h, Vero cell monolayers were inoculated with
KOS or 7134 at m.o.i.s of 0.1, 1, or 10 pfu per cell. After
24 h, cultures were freeze-thawed and the titer of infec-
tious KOS was determined by microtiter plaque assay on
Vero cells, and likewise 7134 titers were determined on
L7 cells.
-Galactosidase assay
-gal activity in 7134-infected Vero cell cultures was
measured as follows. Vero cells were seeded in 24-well
plates (5 104 cells per well), and 6 h later cultures were
treated with vehicle or human IFN- or -. After 14 h, Vero
cell monolayers were inoculated with either (1) 7134
(m.o.i.  1) only or (2) 7134 (m.o.i.  1), Ad.TRE-ICP0
(m.o.i.  10), and Ad.CMV-rtTA (m.o.i.  10). Following
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inoculation the original untreated or IFN-treated culture
medium was returned to each well, and cultures were
treated with 10 M doxycycline and 300 M acyclovir as
indicated in the Results. At times after infection, medium
was replaced with 0.2 ml PBS and cultures were frozen
at 80°C. Once all the samples were collected, culture
lysates were serially diluted fivefold in PBS containing
1% FBS, and -gal activity was measured by its ability to
modify the substrate 0.5 mM chlorophenol red--D-galac-
topyranoside (CPRG; Roche Molecular Biochemicals, In-
dianapolis, IN). In 96-well plates, 40 l of each dilution
was added to 160 l K2HPO4–KH2PO4 buffer (60 mM
each, pH 8.0) containing 1.2 mM MgCl2 and 0.5 mM
CPRG, and the OD570 was measured after 24 h. Quanti-
tation of -gal activity was calculated by multiplying (1)
OD570 times (2) the dilution factor required to bring -gal
activity into the 16- to 32-fold linear range of the assay
(r 2  0.99).
Statistics
With the exception of Fig. 3, the data in all of the other
figures and tables are based on the mean  standard
error (se) observed in a single representative experi-
ment. At least three independent tests were performed
for each of these experiments. The fold-inhibition data
presented in Fig. 3 were calculated by summing across
three independent experiments. All viral titers were
transformed by adding a value of 1 such that all data
could be analyzed on a logarithmic scale. Multiple
groups were compared by one-way analysis of variance
(ANOVA) followed by Tukey’s post hoc t test. Two-way
ANOVA was used to compare fold-inhibition in Vero and
L7 cells or Vero cells infected with Ad.TRE-n212 or
Ad.TRE-ICP0, across multiples doses of IFN-, -, or -.
Likewise, two-way ANOVA was used to compare the
effects of Ad.TRE-ICP0 and ACV on -gal expression in
7134-infected Vero cells treated with human IFN- or -.
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